Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial


Cooper, C., Reginster, J.Y., Chapurlat, R., Christiansen, C., Genant, H., Bellamy, N., Bensen, W., Navarro, F., Badurski, J., Nasonov, E., Chevalier, X. and Sambrook, P.N. (2010) Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Current Medical Research and Opinion, 28, (2), 231-239. (doi:10.1185/03007995.2011.648758). (PMID:22148897).

Download

Full text not available from this repository.

Description/Abstract

The osteoporosis drug strontium ranelate dissociates bone remodelling processes. It also inhibits subchondral bone resorption and stimulates cartilage matrix formation in vitro. Exploratory studies in the osteoporosis trials report that strontium ranelate reduces biomarkers of cartilage degradation, and attenuates the progression and clinical symptoms of spinal osteoarthritis, suggesting symptom- and structure-modifying activity in osteoarthritis. We describe the rationale and design of a randomised trial evaluating the efficacy and safety of strontium ranelate in knee osteoarthritis.

Item Type: Article
ISSNs: 0300-7995 (print)
1473-4877 (electronic)
Related URLs:
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Health Sciences
ePrint ID: 334508
Date Deposited: 08 Mar 2012 10:29
Last Modified: 27 Mar 2014 20:19
URI: http://eprints.soton.ac.uk/id/eprint/334508

Actions (login required)

View Item View Item